BioCentury
ARTICLE | Clinical News

Adynxx planning Phase III for pain candidate despite Phase II miss

April 13, 2018 1:39 PM UTC

Adynxx Inc. (San Francisco, Calif.) said that although brivoligide (AYX1) missed the primary endpoint in the Phase II ADYX-004 trial to treat postsurgical pain, the company still sees a path to Phase III based on subgroup data from the trial. Adynxx plans to start a Phase III trial of brivoligide in early 2019 to treat postsurgical pain in patients with high Pain Catastrophizing Scale (PCS) scores. The candidate is an early growth response 1 (EGR1) inhibitor.

On the primary endpoint in the total population, brivoligide failed to significantly reduce mean pain with walking from days 7-28 after surgery vs. placebo. Adynxx said it is not disclosing detailed data or p-values at this time...

BCIQ Company Profiles

Adynxx Inc.

BCIQ Target Profiles

Early growth response 1 (EGR1)